Media coverage about Fresenius Medical Care (NYSE:FMS) has been trending somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Fresenius Medical Care earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave news coverage about the company an impact score of 46.467851877329 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Here are some of the media stories that may have impacted Accern’s rankings:

Fresenius Medical Care (NYSE FMS) traded down $0.23 during mid-day trading on Tuesday, hitting $50.72. 96,420 shares of the stock traded hands, compared to its average volume of 180,037. The firm has a market capitalization of $31,420.00, a price-to-earnings ratio of 22.31, a PEG ratio of 2.24 and a beta of 0.45. Fresenius Medical Care has a twelve month low of $39.46 and a twelve month high of $51.54. The company has a quick ratio of 0.98, a current ratio of 1.22 and a debt-to-equity ratio of 0.55.

Several brokerages have weighed in on FMS. DZ Bank restated a “buy” rating on shares of Fresenius Medical Care in a research report on Monday, November 13th. Zacks Investment Research lowered shares of Fresenius Medical Care from a “buy” rating to a “sell” rating in a research report on Wednesday, October 25th. Finally, Royal Bank Of Canada restated a “hold” rating and set a $44.00 target price on shares of Fresenius Medical Care in a research report on Wednesday, September 13th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $48.50.

TRADEMARK VIOLATION NOTICE: This article was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another website, it was illegally copied and republished in violation of U.S. and international copyright and trademark law. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/12/05/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-fresenius-medical-care-fms-stock-price.html.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.

Insider Buying and Selling by Quarter for Fresenius Medical Care (NYSE:FMS)

Receive News & Stock Ratings for Fresenius Medical Care Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care Corporation and related stocks with our FREE daily email newsletter.